AXT Assists Vaxine in the Search for a COVID-19 Vaccine
By: AXT Pty Ltd
Vaxine has an established track record with developing vaccines, having already developed formulations for seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy. They started working on a vaccine for COVID-19 in January 2020, before the World Health Organisation had even declared it a global pandemic.
To assist with their research, AXT loaned Vaxine an Etaluma LumaScope LS620. The LS620 is an extremely compact digital inverted light microscope designed for long-term live-cell imaging and suitable for use in incubators and other enclosures.
When asked about Vaxine's COVID-19 research, Dr. Yoshikazu Honda-Okubo, Senior Research Scientist at Vaxine said, "using modelling approaches Vaxine scientists rapidly confirmed that the COVID-19 spike protein binds the same receptor as SARS CoV, namely the human angiotensin-
Richard Trett, Managing Director at AXT commented, "we are pleased that we have been able to contribute, even in a small way to promising Australian research that may pave the way to a vaccine for COVID-19".
The Etaluma Lumascopes are part of AXT's life science portfolio. For details on them and AXT's other solutions for life science research, please visit www.axt.com.au/
Dr. Cameron S. Chai